AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03911921
Drug: RSYRT decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound granules of traditional Chinese medicine
Trial: NCT03911921
Drug: Astragalus membranaceus
RxNorm normalized name: Astragalus membranaceus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One herb
Trial: NCT00338052
Drug: Norethindrone 1 mg / ethinyl estradiol 20 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00110006
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide IV over 30 minutes. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
Trial: NCT00110006
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin IV over 5 minutes. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
Trial: NCT03132194
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical gel
Trial: NCT02296853
Drug: TAF
RxNorm normalized name: Altafed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg tablet administered orally
Trial: NCT01829113
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three loading doses of placebo will be administered intravenously (IV) during a 9 day period. Then placebo (IV) will be given weekly on Days 1, 8 and 15 of each 21 day cycle prior to the administration of pemetrexed (500mg/m\^2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle for a maximum of four treatment cycles. Patients who respond to treatment or have stable disease will continue to receive placebo (IV) plus 500mg/m2 IV pemetrexed weekly until toxicity or disease progression.
Trial: NCT01095679
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breaking tablets of 10 mg of placebo. Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
Trial: NCT01882920
Drug: Goal Directed Intravenous Restrictive Fluid Therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal infusion of crystalloids (normal saline,Ringer's lactate,Ringer's solution) at 4 ml/kg/h and boluses of colloids (HES 130/0.4 ) for values of cardiac index (CI) \<2.5 l/min/m2, stroke volume index (SVI) \< 35 SVI ml/m2 and stroke volume variation (SVV)\> 15%. In the case of CI \<2.5 l/min/m2 and SVI \<35 ml/m2 with SVV \< 15%, an infusion with dopamine was initiated.
Trial: NCT00072072
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01338987
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide: 60 mg/kg intravenous (IV) on days -4 and -3 (for Adults \> 22 years) or Cyclophosphamide: cyclophosphamide 50 mg/kg IV, Days -5, -4, -3, -2. (For Pediatric \</= 22 years)
Trial: NCT01338987
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate:10 mg/m(2) intravenous (IV) on day +1, and 5 mg/m(2) IV Days + 3, 6, 11
Trial: NCT00728780
Drug: ABT-143
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once
Trial: NCT00728780
Drug: ABT-335 and rosuvastatin
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once
Trial: NCT00649727
Drug: Ditropan XL® Tablets 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2x10mg, single dose fed
Trial: NCT02971982
Drug: Velcade/Dexamethasone/cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Velcade:1.3mg/m2,Dexamethasone 10mg q12h,cyclophosphamide 750mg
Trial: NCT00671073
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, oral administration, once daily for 12 weeks
Trial: NCT03697330
Drug: Ringer lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomization will be done using computer generated table of random numbers in a 1:1 ratio and will be conducted using sequentially numbered, opaque and sealed envelope. The trial will be planned that neither the doctors (investigators) nor the patients will be aware of the group allocation and amount of fluid received. Intraoperative and postoperative data collections will be achieved by the same blinded anesthiologist.~Patients will be randomly allocated into two groups:~Group L: 40 patients who will be subjected to ''liberal approach of intraoperative 18-20 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia.~Group R: 40 patients who will be subjected to ''restrictive approach of intraoperative 4-6 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia.~Blood loss will be replaced if more than 500 ml in a ratio of 3 ml crystalloid: 1 ml blood.
Trial: NCT00110344
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle 1. Patients are randomized in a double-blind fashion to receive either Nexavar (see above) or matching placebo (this arm) for 14 days. Dose range will be depending on hematologic and other toxicity between 400mg (2 tablets of 200mg) orally twice bid and 400mg orally every 2 days. Cycle 2 and 3: see above (no placebo application)
Trial: NCT00937651
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01770431
Drug: Huaier Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huaier Granule is a traditional Chinese medicine, 20g / time, 3 times/day,Po.
Trial: NCT00705692
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02328950
Drug: Fludarabine and Cytarabine followed by IV busulfan and cyclophosphamide
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine (F) 30 mg/m²/day for 5 days (day -12 to day-8) Cytarabine (A) 2g/m²/day for 5 days (day -12 to day-8) Bulsufan (Bu) 0.8mg/kg/day for 3 days (day -7 to day-5) Cyclophosphamide(Cy) 1.8g/m²/day for 3 days (day -4 to day-3)
Trial: NCT02408328
Drug: Caffeine citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loading dose and continues use of caffeine until 44 weeks postmenstrual age
Trial: NCT01843348
Drug: Enteric Coated Mycophenolate Sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets: 180 mg or 360 mg. Dosing: duration of study 360 mg bid and no less than 360 mg daily dose
Trial: NCT01843348
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A minimum dose of 5 mg prednisolon or equivalent
Trial: NCT02234206
Drug: Chandrakanthi Choornam (CKC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12gm in milk - OD dose; Oral route; 3 Months ( 90days) - duration~Preparation from approved sastric book as per drugs \& cosmetic act 1940
Trial: NCT03994549
Drug: Dual GLP-1/GLP-2 Receptor agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eight ascending doses of ZP7570
Trial: NCT03465436
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered for lasmiditan or moxifloxacin
Trial: NCT03347513
Drug: triple attack therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eradication of H-pylori using triple attack therapy.
Trial: NCT03347513
Drug: Ferrous(II)-glycine-sulphate complex 567.7 mg capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron therapy will be given to both groups twice daily for one month.
Trial: NCT06490003
Drug: Fluoro Uracil
RxNorm normalized name: Fluoro Uracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Esophageal cancer chemotherapy（First line treatment)
Trial: NCT01933464
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03832738
Drug: Placebo Tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matching in appearance to the active drug tablets
Trial: NCT04176588
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug:placebo Tablet
Trial: NCT00002714
Drug: Stanford V regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002714
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03580291
Drug: Placebo of Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The group receive placebo of oral mycophenolate mofetil.
Trial: NCT00925301
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule QOD
Trial: NCT02046668
Drug: spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: spironolactone 25mg daily for 12 weeks
Trial: NCT04334629
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lipid ibuprofen 200 mg
Trial: NCT04465539
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone dose is 200-300 mg /day intravenously
Trial: NCT00603291
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet each morning and evening for a duration of 52 weeks.
Trial: NCT03326674
Drug: Tesetaxel and Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tesetaxel plus reduced dose of Capecitabine
Trial: NCT03326674
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine alone at approved dose
Trial: NCT00293202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemodialysis patients will receive Saline by subcutaneous injection twice a week
Trial: NCT04465539
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: received the standard ALP treatment according to TUPTC protocol as follows: patient resuscitation, care of airway, breathing and circulation, gastric decontamination with 2 ampoules sodium bicarbonate (each ampoule 25 ml containing 2.1 gm sodium bicarbonate) followed by activated charcoal in dose of 1 g/Kg orally, adequate hydration, normal saline administration (0.9% Sodium Chloride IV), vasopressors IV infusions, inhalation of 100% oxygen, ranitidine IV, magnesium sulfate IV infusion and other supportive treatment.
Trial: NCT01450839
Drug: E2022
RxNorm normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE2022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment period consists of 2 periods, Period I and Period II. In Period I, one 5 mg E2020 tablet will be administered in a single dose. In Period II, the tape containing 16 mg E2022 (which corresponds to one 5 mg E2020 tablet) will be applied repeatedly for 17 days. A washout period of at least 8 days will be allowed between the day of single dose administration in Period I and the first day of repeated application in Period II. A post-treatment examination will be performed at least 21 days after the last removal of the investigational product in Period II.
Trial: NCT01450839
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo tablets and tape
Trial: NCT01288469
Drug: Placebo (for alirocumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One SC injection in the abdomen only.
Trial: NCT01288469
Drug: Placebo (for atorvastatin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One over-encapsulated tablet of placebo for atorvastatin orally once daily in the evening with dinner.
Trial: NCT00331071
Drug: Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: worn for 1 week and replaced for 3 consecutive weeks
Trial: NCT04715997
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline
Trial: NCT00408564
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01763749
Drug: Closone
RxNorm normalized name: erythromycin estolate Oral Capsule [Ilosone]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closone 75mg/100mg, 4weeks, PO
Trial: NCT01763749
Drug: Plavix with Astrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plavix 75mg with Astrix 100mg, 4weeks, PO
Trial: NCT01060930
Drug: Intravenous infusion of L-NMMA and Nor-epinephrine
RxNorm normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 3mg/kg L-NMMA (L-NG-monomethyl arginine; NO synthase inhibitor) and nor-epinephrine at 50 ng/kg/min. Each infusion to run over 15 mins and separated by 45 min to allow return to baseline. Drugs infused in a randomised order. During the study, blood pressure will be measured invasively using an intra-arterial radial artery cannula, central arterial stiffness measured using peripheral arterial tonometry and cardiac output using thoracic bioimpedance.
Trial: NCT01674413
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 syringe of placebo SC q 2 weeks, with additional placebo loading of 3 syringes/1 syringe at Weeks 0/2, 12/14, 24/26, and 36/38 Weeks.
Trial: NCT04254835
Drug: Cervitec F, Ivoclar Vivadent - Schaan Liechtenstein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride varnish containing Chlorhexidine and Cetylpyridinium Chloride
Trial: NCT04254835
Drug: Fluor Protector, Ivoclar Vivadent - Schaan Liechtenstein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Fluoride varnish
Trial: NCT01861236
Drug: Firmagon® (degarelix)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly subcutaneous injections
Trial: NCT00560937
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (similar to active comparator) 50 mg BID x 2 weeks, Placebo (similar to active comparator) 150 mg BID x 2 weeks, Placebo (similar to active comparator) 250 mg BID x 4 weeks
Trial: NCT02243293
Drug: ABT-493
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT02243293
Drug: ABT-530
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT02243293
Drug: ABT-493/ABT-530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet; ABT-493 co-formulated ABT-530
Trial: NCT02736682
Drug: Single dose antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose arm receive 2g of IV Ceftriaxone and 500 mgs ofIntra venous Metronidazole given to the mothers 30-60 minutes pre operative.
Trial: NCT02736682
Drug: Multiple dose antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose arm receive 1 g of IV Cetriaxone plus 500 mgs during surgery and there after IV ceftriaxone once a day for 3 days and IV Metronidazole 500mgs during surgery and there after every 8 hours for 3 days.
Trial: NCT00191789
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m\^2, IV, every 21 days x 4 cycles (1-4)
Trial: NCT02287129
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 625 mg/m2
Trial: NCT02701231
Drug: Systemic anti-tumor therapy
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic anti-tumor therapy includes targeted therapies, chemotherapy and best supportive care, according to NCCN non-small cell lung cancer(NSCLC) and small cell lung cancer(SCLC) guidelines. SCLC patients will receive six cycles of cisplatin and etoposide. NSCLC patients will receive EGFR and ALK test. With sensitive result the first-line therapy will be Erlotinib/Gefitinib/Crizotinib. If insensitive, the patient will receive six cycles of cisplatin and pemetrexed. Then the patient will receive tumor response evaluation. The patient with response or stable disease will receive maintenance therapy with one or some of the drugs including bevacizumab, pemetrexed, gemcitabine and docetaxel until disease progression. During experience all patients will receive clinical observation. Once proven for disease progression the patient will finish the experiment.
Trial: NCT01359423
Drug: Percutaneous transluminal angioplasty of femoropopliteal artery lesions with primary long
RxNorm normalized name: scabies lesion lysate (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
Trial: NCT04356118
Drug: intrathcal methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal chemotherapy specified dose on specified days.
Trial: NCT00692146
Drug: AZD1386
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution fixed dose (95 mg given orally on two occasions)
Trial: NCT00692146
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution fixed dose (95 mg given orally on two occasions)
Trial: NCT03629600
Drug: Rectal Form Indometacin
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-ERCP rectal administration of 100 MG Indomethacin
Trial: NCT01452594
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03863483
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride injection as placebo will be administered intravenously at a fixed dose of 100 milliliters (mL) on Day 1 of each 21-day cycle.
Trial: NCT02316249
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
Trial: NCT03235076
Drug: BAY1101042
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 10 mg BAY 1101042 (given as 5 mg MR tablets)
Trial: NCT00633386
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg oral capsule as a single dose 1 hour prior to surgery and 200 mg oral capsule as a single dose as needed post-surgery
Trial: NCT01414075
Drug: Oral Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered per oral dose and schedule specified in the arm.
Trial: NCT01414075
Drug: IV Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered per IV dose and schedule specified in the arm.
Trial: NCT03151460
Drug: Dopamine Agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were assessed in two experimental conditions that were performed on different days, with an intersession interval of about one month. In the off condition PD subjects performed the experimental tasks in the morning after 12/18 hours of Dopamine Agent withdrawal. In the on condition they were examined 90-120 minutes after they had taken their first morning dose of levodopa and/or dopamine agonists.
Trial: NCT01300052
Drug: AN2728 ointment, 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AN2728 ointment, 2%, applied twice daily for 12 weeks
Trial: NCT00887328
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug
Trial: NCT00741611
Drug: Anti-arrhythmic drugs
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 anti-arrhythmic drugs administered at the labeled dosage for atrial fibrillation
Trial: NCT02859948
Drug: SKLB1028
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKLB1028 capsules in six doses beginning at 20 mg and rising to 200 mg.
Trial: NCT01859767
Drug: [123I]MNI-672 SPECT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be dosed by intravenous injection to a target dose of 5 mCi and not to exceed 5.5 (not \>10% of 5 mCi limit) I-123 MNI-672 prior to the SPECT scan.
Trial: NCT01286324
Drug: Placebo Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01124136
Drug: Standard of Care (Control)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care Therapy consists of medication management only to support heart for rhythm, anticoagulation, and rate, and comorbid symptoms, i.e. diuretics, lipid lowering.
Trial: NCT00027859
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03334448
Drug: LY900014-U200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03334448
Drug: LY900014-U100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT00290251
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo given once daily for 3 menstrual cycles or 90 - 102 days